Access to Kitabis Pak Expands for Patients with Cystic Fibrosis

RICHMOND, Va., July 21, 2015 /PRNewswire/ -- There is positive news for patients with cystic fibrosis using nebulized antibiotic therapy as access to Kitabis Pak has expanded in many US states. Kitabis Pak is now on the Preferred Drug List (PDL) for many state programs, increasing access to the only FDA approved co-packaging of tobramycin inhalation solution together with the PARI LC PLUS nebulizer handset.  Each carton of Kitabis Pak contains a 28-day course of generic tobramycin inhalation solution and the PARI LC PLUS nebulizer handset, the only nebulizer handset approved for the delivery of tobramycin inhalation solution. For specific information regarding your state, please visit www.Kitabis.com/patient-access/PDL

"Patients with CF that are covered by these Medicaid plans, and prescribed Kitabis Pak will have complete access to the only nebulizer handset used in the clinical trials for tobramycin inhalation solution," said Lisa Cambridge, MSHS, RRT, director of Medical Science & Pharmaceutical Alliances at PARI. "The goal of Kitabis Pak is to increase patient access through this strategic co-packaging of both drug and device in one box." 

Kitabis Pak is therapeutically equivalent to TOBI (tobramycin inhalation solution, USP) carrying the AN designation in the FDA's Orange Book.

"Expanded patient access to Kitabis Pak is welcome news for both CF patients and healthcare professionals," says Mary Lester, RRT, RCP. "A new LC PLUS nebulizer handset co-packaged with each course of drug not only improves patient access to the right device, but also helps maintain drug delivery and address the challenges of nebulizer maintenance and acquisition."

About Kitabis Pak

Kitabis Pak (co-packaging of tobramycin inhalation solution and the PARI LC PLUS Reusable Nebulizer) is indicated for the management of cystic fibrosis in adults and pediatric patients 6 years of age and older with P. aeruginosa. Safety and efficacy have not been demonstrated in patients under the age of 6 years, patients with FEV1 <25% or >75% predicted, or patients colonized with Burkholderia cepacia.

Full product and prescribing information on Kitabis Pak is online at: www.Kitabis.com.

About Cystic Fibrosis

Cystic fibrosis, a life-threatening disease affecting 30,000 American patients, involves a genetic mutation that results in poorly hydrated, thickened mucus secretions in the lungs.

About PARI Respiratory Equipment, Inc. PARI is a leading, worldwide developer and manufacturer of fast and efficient aerosol delivery systems for patients with asthma, chronic lung disease, cystic fibrosis, RSV, VAP, and HAP.  PARI's worldwide mission is to improve the lives of those affected by respiratory diseases and those who provide care for them. This is reflected in our comprehensive portfolio of innovative products. PARI is considered the gold standard in aerosol delivery for nebulizer therapies.  Featured products include the PARI LC PLUS Reusable Nebulizer, Vortex^® Holding Chamber, and the drug-specific eFlow Technology platform.

SOURCE PARI Respiratory Equipment

Related Links

http://www.Kitabis.com